Clevidipine
کلودیپین
❤️ Cardiovascular SystemIV calcium channel blocker
Market / country: 🇺🇸 USA
Cleviprex (US)
🧮 Dose calculator
Hypertensive emergency (hospital) · Regimen source: FDA Cleviprex · 2.2
- • Double every 90 s initially; near goal less-than-double every 5–10 min. Most patients ≤16 mg/h; because of lipid load, no more than 1000 mL or an average 21 mg/h per 24 h. FDA Cleviprex · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Soy or egg allergy; defective lipid metabolism; severe aortic stenosis. FDA Cleviprex · 4
Warnings
- • Hypotension and reflex tachycardia; lipid emulsion (aseptic technique); rebound hypertension up to 8 h after stopping. FDA Cleviprex · 5FDA Cleviprex · 2.1
Formulations
- 0.5 mg/mL emulsion (50, 100, 250 mL) — injection 🇺🇸 USA FDA Cleviprex · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Cleviprex · 8.1
“Pregnancy Category C There are no adequate and well-controlled studies of Cleviprex use in pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Cleviprex · 8.3
“Because many drugs are excreted in human milk, consider possible infant exposure when Cleviprex is administered to a nursing woman.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Cleviprex · 8.4
“The safety and effectiveness of Cleviprex in children under 18 years of age have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Cleviprex · 8.5
“In general, for an elderly patient doses should be titrated cautiously, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA022156
- DailyMed (FDA label)FDA Cleviprex
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDC08CA16
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Cleviprex · 3FDA Cleviprex · 2.2FDA Cleviprex · 4FDA Cleviprex · 5FDA Cleviprex · 2.1FDA Cleviprex · SPL approval / marketing categoryFDA Cleviprex · 8.1FDA Cleviprex · 8.3FDA Cleviprex · 8.4FDA Cleviprex · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified